Kobayashi Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) shareholders are probably feeling a little disappointed, since its shares fell 2.1% to JP¥5,473 in the week after its latest half-year results. It looks like a pretty bad result, all things considered. Although revenues of JP¥71b were in line with analyst predictions, statutory earnings fell badly short, missing estimates by 94% to hit JP¥1.34 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, the most recent consensus for Kobayashi Pharmaceutical from eight analysts is for revenues of JP¥172.8b in 2026. If met, it would imply a satisfactory 3.2% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to shoot up 526% to JP¥137. Before this earnings report, the analysts had been forecasting revenues of JP¥172.5b and earnings per share (EPS) of JP¥140 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.
View our latest analysis for Kobayashi Pharmaceutical
It might be a surprise to learn that the consensus price target was broadly unchanged at JP¥5,496, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Kobayashi Pharmaceutical analyst has a price target of JP¥6,700 per share, while the most pessimistic values it at JP¥3,950. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Kobayashi Pharmaceutical's rate of growth is expected to accelerate meaningfully, with the forecast 6.4% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 1.4% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 3.7% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Kobayashi Pharmaceutical to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at JP¥5,496, with the latest estimates not enough to have an impact on their price targets.
With that in mind, we wouldn't be too quick to come to a conclusion on Kobayashi Pharmaceutical. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Kobayashi Pharmaceutical going out to 2028, and you can see them free on our platform here..
However, before you get too enthused, we've discovered 3 warning signs for Kobayashi Pharmaceutical (1 doesn't sit too well with us!) that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.